Bernhard R. M. Ehmer

Bernhard R.
M.
Ehmer currently works at Biotest AG, as Chairman-Supervisory Board from 2022, Achilles Therapeutics Plc, as Independent Non-Executive Director from 2022, Affimed NV, as Independent Member-Supervisory Board from 2016, and Affimed GmbH, as Member-Supervisory Board from 2016.
Dr. Ehmer also formerly worked at Biopheresis GmbH, as Chief Executive Officer & Managing Director from 2006 to 2007, BioPheresis Technologies, Inc., as Chief Executive Officer & Managing Director from 2006 to 2007, Neovii Biotech GmbH, as President & Chief Executive Officer from 2007 to 2008, Biotest AG, as Chairman-Management Board from 2015 to 2019, Symphogen A, as Chairman from 2018 to 2020, ADMA Biologics, Inc., as Director from 2017 to 2018, Hybrigenics SA, as Director, ImClone Systems International GmbH, as Managing Director & Senior Vice President from 2008 to 2012, Merck KGaA, as VP, Head-Strategic Planning & Alliance Management from 1988 to 2006, Merck KGaA, as Head-Clinical Research & Development Operations from 1998 to 2006, Boehringer Mannheim GmbH, as Head-Therapeutics & Medical Operations from 1986 to 1998, and ImClone Systems Corp., as President from 2009 to 2014.
Dr. Ehmer received his undergraduate degree in 1982 from Ruprecht-Karls-Universität Heidelberg and undergraduate degree in 1982 from Ludwig-Maximilians-Universität München.